|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||36.51|
|Forward Dividend & Yield||1.43 (1.34%)|
|1y Target Est||N/A|
Analysts are bullish on these following companies: Class, Imdex, CSL. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. Below I’veRead More...
The global biotherapeutics company will to pay $91 million cash and $325 million in milestones to acquire venture-backed Calimmune Inc. and its potential gene therapy for two rare blood disorders.
Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
Twice a week, thousands of people across the U.S. roll up their sleeves and give almost a liter of their blood plasma -- which will eventually be made into dozens of pharmaceutical products.